108
Participants
Start Date
November 30, 2006
Primary Completion Date
January 31, 2009
Study Completion Date
June 30, 2009
loteprednol etabonate/tobramycin opthalmic suspension
Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
vehicle
topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Pediatric Ophthalmology of Erie, Erie
Bausch & Lomb Incorporated
INDUSTRY